The HLA-A2402–restricted epitopes for this therapy included two that had been previously identified and evaluated for safety and potent immunogenicity in cancer patients: a VEGFR1-derived peptide (VEGFR1-1084) [28] and a VEGFR2-derived peptide (VEGFR2-169) [29, 30]. The gene discussed is KDR; the disease is cancer.